The Treatment of Shoulder-hand Syndrome in Hemiplegia Patients (NCT07245472) | Clinical Trial Compass
CompletedNot Applicable
The Treatment of Shoulder-hand Syndrome in Hemiplegia Patients
China84 participantsStarted 2023-11-01
Plain-language summary
The purpose of this clinical study is to investigate effects of Kinesio taping (KT) combined with dry needling (DN) on myofascial trigger points (MTrPs) in post-stroke hemiplegic shoulder-hand syndrome (SHS).
Methods: A prospective, double-blind randomized controlled trial was conducted on 84 SHS patients, who were randomized into three groups: DN (Group A), KT (Group B), and DN+KT (Group C), all receiving standard rehabilitation. VAS, ADL, FMA-UE, PROM, and 8-figure dimensional difference were assessed pre- and post-28-day treatment. Statistical analysis was performed using SPSS 27.0, with paired t-test for intragroup comparisons and independent sample t-test for intergroup comparisons, and statistical significance was set at P\<0.05.
Who can participate
Age range
40 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Within the recovery period from stroke with stable vital signs
* Diagnosis of Stage I shoulder-hand syndrome (SHS)
* SHS onset within 3 months prior to enrollment
* Aged between 40 and 80 years
* Willingness to participate in the trial and provision of signed informed consent
Exclusion Criteria:
* SHS caused by brain trauma or other non-stroke etiologies
* History of shoulder or neck pain due to cervical spondylosis or scapulohumeral periarthritis
* Diagnosis of malignant tumors
* Presence of psychotic disorders or other severe systemic diseases
* Coagulation disorders
* Skin allergies or leukemia contraindicating acupuncture treatment
* Known skin allergy to Kinesio tape
* Concurrent participation in other traditional Chinese medicine or interventional therapies during the trial period
* Joint pain or dyskinesia resulting from peripheral neuropathy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Pain Intensity
Timeframe: Baseline, 14 days, and 28 days post-treatment.
2
Upper Limb Motor Function
Timeframe: Baseline, 14 days, and 28 days post-treatment.